Redhill Biopharma (RDHL)
(Delayed Data from NSDQ)
$0.46 USD
0.00 (0.07%)
Updated May 10, 2024 04:00 PM ET
After-Market: $0.46 0.00 (0.37%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
RDHL 0.46 0.00(0.07%)
Will RDHL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RDHL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RDHL
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug
RDHL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Redhill Biopharma Ltd. (RDHL) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Other News for RDHL
Odysight.ai Announces Appointment of Einav Brenner as Chief Financial Officer
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
RedHill Biopharma Secures Opaganib Patent in China
RedHill Biopharma issued Chinese patent Notice of Allowance covering opaganib
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study